Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 18/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL7831396 | 0.98 | FDPS (0.76) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5608575 | 0.96 | FDPS (0.73) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5608824 | 0.94 | FDPS (0.70) | FDPSPDE3ALMNAADRB3PDE4D | |
| Neridronic Acid SCHEMBL10607521 | 0.92 | FDPS (0.75) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3389 | 0.90 | FDPS (0.68) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL328770 | 0.88 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4270336 | 0.88 | FDPS (0.87) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5973516 | 0.88 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL536413 | 0.88 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4421548 | 0.88 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117100769-A | Bone-targeting engineering bacteria outer vesicle and preparation method and application thereof | 上海大学 | 2023-11-24 | — | — | CN | claimed |
| CN-107118870-A | A kind of glass cleaner and its preparation technology | 合肥钢骨玻璃制品有限公司 | 2017-09-01 | — | — | CN | claimed |
| EP-2054029-B9 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LTD (IE) | 2011-02-02 | — | — | EP | claimed |
| EP-2054029-B1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LTD (IE) | 2010-06-23 | — | — | EP | claimed |
| US-20100062037-A1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARAMCEUTICALS LIMITED (IE) | 2010-03-11 | — | — | US | claimed |
| US-20100003298-A1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDER PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LTD. (IE) | 2010-01-07 | — | — | US | claimed |
| EP-2054037-B1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LTD (IE) | 2009-12-16 | — | — | EP | claimed |
| EP-2054029-A1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | Mediolanum Pharmaceuticals Limited (IE) | 2009-05-06 | — | — | EP | claimed |
| EP-2054037-A2 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | Mediolanum Pharmaceuticals Limited (IE) | 2009-05-06 | — | — | EP | claimed |
| CN-101139361-A | Targeted anti-osteoporosis medicine and preparation method thereof | WEST CHINA HOSPITAL SICHUAN UNIV (CN) | 2008-03-12 | — | — | CN | claimed |
| WO-2008015236-A1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LTD. (IE) | 2008-02-07 | — | — | WO | claimed |
| WO-2008015238-A2 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MEDIOLANUM PHARMACEUTICALS LTD. (IE) | 2008-02-07 | — | — | WO | claimed |
| US-20010021705-A1 | Disodium alendronate formulations | MERCK & CO., INC. | 2001-09-13 | — | — | US | claimed |
| EP-0837863-A4 | DISODIUM ALENDRONATE FORMULATIONS | MERCK & CO INC (US) | 1999-06-16 | — | — | EP | claimed |
| EP-0837863-A1 | DISODIUM ALENDRONATE FORMULATIONS | Merck & Co., Inc. (US) | 1998-04-29 | — | — | EP | claimed |
| WO-1996039410-A1 | DISODIUM ALENDRONATE FORMULATIONS | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | claimed |
| CN-112672747-B | Peptides for activating cell signaling in osteoprogenitor cells | 加利福尼亚大学董事会 | 2025-02-18 | — | — | CN | disclosed |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-03 | — | — | US | disclosed |
| US-5227506-A | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors | MERCK & CO., INC. (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0416689-A2 | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors | MERCK & CO. INC. (US) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062037-A1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME | MGAM, MMP1, LPXN | FDPS 3330/4885PDE3A 1003/4885LMNA 2735/4885 |
| US-20100003298-A1 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDER PERIOD OF TIME | PGA5, PGM2, PYGM | FDPS 2579/4885PDE3A 79/4885LMNA 3322/4885 |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | ITGB4, ITGA4, ITGB1 | FDPS 3136/4885PDE3A 3028/4885LMNA 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.